Table 2 Characteristics of included studies
Author, year | Study area | Study design | Sample size | Sex | Participants on | Bromocriptine effect | P value, OR of HR | Duration of follow up | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
M | F | Bromocriptine | Placebo | |||||||||||
HbA1 | Fasting glucose | BMI Or CV risk | HbA1 | FPG | BMI Or CV risk | |||||||||
Aminorroaya et al. [5] | Asia (Iran) | RCT | 40 | 6 | 34 | 20 | 20 | Reduced compared with the placebo | Reduced | No change | p < 0.01 | P < 0.05 | 52wks | |
Chamarthi et al. [8] | USA (Boston) | RCT | 1834 | 1008 | 826 | 1219 | 615 | Reduced | Reduced | Reduced | p=0.002 | p=0.002 | HR: 0.52 [0.28 − 0.98 | 18wks |
Bindu et al. [9] | Boston | RCT | 1791 | 1025 | 765 | 1208 | 583 | Reduced | Reduced | Reduced | P < 0.003 | P < 0.001 | HR: 0.45(p = 0.028 | 52wks |
Cincotta et al. [12] | Charlestown and massachusetts | RCT | 17 | 10 | 7 | 10 | 7 | Reduced | Reduced | Reduced | P < 0.02 | P < 0.02 | P < 0.01 | 18wks |
Chamarthi and Cincotta [16] | USA (Bonton) | RCT | 60 | 50 | 10 | 44 | 16 | Reduced | No significant difference | NA | P < 0.001 | P = 0.49 | NA | 12wks |
Pijl et al. [1] | San Antonio | RCT | 22 | 8 | 14 | 15 | 7 | Reduced | Reduced | No change | P = 0.009 | P < 0.02 | P > 0.13 | 16wks |
Gaziano et al. [11] | USA(multicenter) | RCT | 3070 | 1739 | 1331 | 2054 | 1016 | Reduce | Reduced | Significant reduction | P = 0.12 | 0.12 | 52%reduction in relative risk(p < 0.05) | 52wks |
Gaziano et al. [2] | Charlestown and massachusetts | RCT | 2557 | 1739 | 818 | 1643 | 914 | Reduced | Reduced | Reduced | P < 0.05 | P < 0.05 | P < 0.001 | 24wks |